In 2022 the FDA warned, based on adverse event reports, that transmucosal (sublingual and buccal) buprenorphine may cause dental problems, such as tooth decay, cavities, oral infections, or loss of teeth. This study used insurance claims data from 2002 to 2019 for more than 700,000 adults with OUD; 22% had received transmucosal buprenorphine (3 or more prescriptions in 6 months) and the remaining 78% served as controls. The authors found that transmucosal buprenorphine was associated with increased oral health problems compared to controls at all time points from 1 month to 5 years.

Read more: https://journals.lww.com/journaladdictionmedicine/abstract/9900/risk_of_oral_health_problems_in_adults_with_opioid.470.aspx